Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 726

1.

Successful implementation of genomically based treatment of chemotherapy refractory peripheral T-cell lymphoma (PTCL).

Galanina N, Kurzrock R.

Cancer Biol Ther. 2018 Oct 11:1-5. doi: 10.1080/15384047.2018.1523857. [Epub ahead of print]

PMID:
30307363
2.

Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology.

Jardim DL, de Melo Gagliato D, Kurzrock R.

Integr Cancer Ther. 2018 Sep 19:1534735418801524. doi: 10.1177/1534735418801524. [Epub ahead of print]

PMID:
30229677
3.

Advanced Basal Cell Cancer: Concise Review of Molecular Characteristics and Novel Targeted and Immune Therapeutics.

Nikanjam M, Cohen PR, Kato S, Sicklick JK, Kurzrock R.

Ann Oncol. 2018 Sep 14. doi: 10.1093/annonc/mdy412. [Epub ahead of print]

PMID:
30219896
4.

GNAS, GNAQ, and GNA11 Alterations in Patients With Diverse Cancers.

Parish AJ, Nguyen V, Goodman AM, Murugesan K, Frampton GM, Kurzrock R.

Cancer. 2018 Sep 11. doi: 10.1002/cncr.31724. [Epub ahead of print]

PMID:
30204251
5.

Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade.

Galanina N, Goodman AM, Cohen PR, Frampton GM, Kurzrock R.

Cancer Immunol Res. 2018 Oct;6(10):1129-1135. doi: 10.1158/2326-6066.CIR-18-0121. Epub 2018 Sep 7.

PMID:
30194084
6.

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.

van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC.

Blood. 2018 Sep 4. pii: blood-2018-07-862334. doi: 10.1182/blood-2018-07-862334. [Epub ahead of print]

PMID:
30181172
7.

Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies.

Kato S, Ross JS, Gay L, Dayyani F, Roszik J, Subbiah V, Kurzrock R.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00235. Epub 2018 Jul 13.

8.

Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer.

Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong D, Kurzrock R, Hortobagyi GN, Janku F, Moulder SL.

Oncologist. 2018 Aug 23. pii: theoncologist.2017-0498. doi: 10.1634/theoncologist.2017-0498. [Epub ahead of print]

PMID:
30139837
9.

Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors.

Subbiah IM, Tang C, Rao A, Falchook GS, Subbiah V, Tsimberidou AM, Karp D, Kurzrock R, Hong DS.

Oncotarget. 2018 Jun 22;9(48):28842-28848. doi: 10.18632/oncotarget.25571. eCollection 2018 Jun 22.

10.

Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival.

Baumgartner JM, Raymond VM, Lanman RB, Tran L, Kelly KJ, Lowy AM, Kurzrock R.

Ann Surg Oncol. 2018 Aug;25(8):2400-2408. doi: 10.1245/s10434-018-6561-z. Epub 2018 Jun 14.

11.

Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.

Goodman AM, Piccioni D, Kato S, Boichard A, Wang HY, Frampton G, Lippman SM, Connelly C, Fabrizio D, Miller V, Sicklick JK, Kurzrock R.

JAMA Oncol. 2018 Sep 1;4(9):1237-1244. doi: 10.1001/jamaoncol.2018.1701.

12.

MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis.

Ikeda S, Schwaederle M, Mohindra M, Fontes Jardim DL, Kurzrock R.

J Hematol Oncol. 2018 Jun 4;11(1):76. doi: 10.1186/s13045-018-0610-8.

13.

Reply to J.J. Tao et al.

Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R.

J Clin Oncol. 2018 Aug 10;36(23):2451. doi: 10.1200/JCO.2018.78.6392. Epub 2018 Jun 1. No abstract available.

PMID:
29856693
14.

Cancer research in the United States: A critical review of current status and proposal for alternative models.

Kantarjian HM, Prat F, Steensma DP, Kurzrock R, Stewart DJ, Sekeres MA, Leveque J.

Cancer. 2018 Jul 15;124(14):2881-2889. doi: 10.1002/cncr.31522. Epub 2018 May 14. No abstract available.

PMID:
29757456
15.

Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers.

Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, Subbiah V, Kurzrock R, Byers L, Westin S, Lim J, Bean S, Bass A, Nguyen L, Meric-Bernstam F, Hong D.

Br J Cancer. 2018 May;118(11):1419-1424. doi: 10.1038/s41416-018-0068-z. Epub 2018 Apr 26.

PMID:
29695765
16.

Razelle Kurzrock and Shumei Kato on Immunotherapy and Hyperprogression of Disease.

Kurzrock R, Kato S.

Oncology (Williston Park). 2018 Apr 15;32(4):150-1, 163. No abstract available.

17.

The importance of greater speed in drug development for advanced malignancies.

Stewart DJ, Stewart AA, Wheatley-Price P, Batist G, Kantarjian HM, Schiller J, Clemons M, Bradford JP, Gillespie L, Kurzrock R.

Cancer Med. 2018 May;7(5):1824-1836. doi: 10.1002/cam4.1454. Epub 2018 Mar 30.

18.

TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [18F] fluorodeoxyglucose (18F-FDG PET).

Chang GH, Kurzrock R, Tran L, Schwaederle M, Hoh CK.

Oncotarget. 2018 Feb 16;9(18):14306-14310. doi: 10.18632/oncotarget.24508. eCollection 2018 Mar 6.

19.

JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis.

Choi MY, Kato S, Wang HY, Lin JH, Lanman RB, Kurzrock R.

Cancer Biol Ther. 2018 Aug 3;19(8):664-668. doi: 10.1080/15384047.2018.1450120.

20.

Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial.

Maitland ML, Piha-Paul S, Falchook G, Kurzrock R, Nguyen L, Janisch L, Karovic S, McKee M, Hoening E, Wong S, Munasinghe W, Palma J, Donawho C, Lian GK, Ansell P, Ratain MJ, Hong D.

Br J Cancer. 2018 Apr;118(8):1042-1050. doi: 10.1038/s41416-018-0020-2. Epub 2018 Mar 19.

21.

Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma.

Ikeda S, Tsigelny IF, Skjevik ÅA, Kono Y, Mendler M, Kuo A, Sicklick JK, Heestand G, Banks KC, Talasaz A, Lanman RB, Lippman S, Kurzrock R.

Oncologist. 2018 May;23(5):586-593. doi: 10.1634/theoncologist.2017-0479. Epub 2018 Feb 27.

PMID:
29487225
22.

Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics.

Ikeda S, Lim JS, Kurzrock R.

Mol Cancer Ther. 2018 May;17(5):1114-1122. doi: 10.1158/1535-7163.MCT-17-0604. Epub 2018 Feb 26.

PMID:
29483209
23.

Challenging Standard-of-Care Paradigms in the Precision Oncology Era.

Subbiah V, Kurzrock R.

Trends Cancer. 2018 Feb;4(2):101-109. doi: 10.1016/j.trecan.2017.12.004. Epub 2018 Jan 12. Review.

PMID:
29458960
24.

Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies.

Goodman AM, Kato S, Cohen PR, Boichard A, Frampton G, Miller V, Stephens PJ, Daniels GA, Kurzrock R.

Oncoimmunology. 2017 Dec 22;7(3):e1404217. doi: 10.1080/2162402X.2017.1404217. eCollection 2018.

25.

Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus.

Schrock AB, Pavlick D, Klempner SJ, Chung JH, Forcier B, Welsh A, Young L, Leyland-Jones B, Bordoni R, Carvajal RD, Chao J, Kurzrock R, Sicklick JK, Ross JS, Stephens PJ, Devoe C, Braiteh F, Ali SM, Miller VA.

Clin Cancer Res. 2018 Apr 15;24(8):1881-1890. doi: 10.1158/1078-0432.CCR-17-3103. Epub 2018 Jan 23.

26.

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R.

J Clin Oncol. 2018 Feb 20;36(6):536-542. doi: 10.1200/JCO.2017.75.3780. Epub 2018 Jan 10.

PMID:
29320312
27.

Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors.

Jardim DL, de Melo Gagliato D, Giles FJ, Kurzrock R.

Clin Cancer Res. 2018 Apr 15;24(8):1785-1794. doi: 10.1158/1078-0432.CCR-17-1970. Epub 2017 Dec 6. Review.

PMID:
29212781
28.

Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients.

Schwaederle M, Krishnamurthy N, Daniels GA, Piccioni DE, Kesari S, Fanta PT, Schwab RB, Patel SP, Parker BA, Kurzrock R.

Cancer. 2018 Mar 15;124(6):1288-1296. doi: 10.1002/cncr.31175. Epub 2017 Dec 6.

29.

Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining "Actionability" of a Molecular Lesion and Patient Management Support.

Chae YK, Pan AP, Davis AA, Patel SP, Carneiro BA, Kurzrock R, Giles FJ.

Mol Cancer Ther. 2017 Dec;16(12):2645-2655. doi: 10.1158/1535-7163.MCT-17-0597. Review.

PMID:
29203694
30.

Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors.

Krishnamurthy N, Kurzrock R.

Cancer Treat Rev. 2018 Jan;62:50-60. doi: 10.1016/j.ctrv.2017.11.002. Epub 2017 Nov 13. Review.

PMID:
29169144
31.

Core Clinical Data Elements for Cancer Genomic Repositories: A Multi-stakeholder Consensus.

Conley RB, Dickson D, Zenklusen JC, Al Naber J, Messner DA, Atasoy A, Chaihorsky L, Collyar D, Compton C, Ferguson M, Khozin S, Klein RD, Kotte S, Kurzrock R, Lin CJ, Liu F, Marino I, McDonough R, McNeal A, Miller V, Schilsky RL, Wang LI.

Cell. 2017 Nov 16;171(5):982-986. doi: 10.1016/j.cell.2017.10.032.

PMID:
29149611
32.

Molecular Tumor Boards: Realizing Precision Oncology Therapy.

Patel M, Kato SM, Kurzrock R.

Clin Pharmacol Ther. 2018 Feb;103(2):206-209. doi: 10.1002/cpt.920. Epub 2017 Nov 14.

PMID:
29134641
33.

The Mutational Landscape of Gastrointestinal Malignancies as Reflected by Circulating Tumor DNA.

Riviere P, Fanta PT, Ikeda S, Baumgartner J, Heestand GM, Kurzrock R.

Mol Cancer Ther. 2018 Jan;17(1):297-305. doi: 10.1158/1535-7163.MCT-17-0360. Epub 2017 Nov 13.

PMID:
29133621
34.

Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study.

Tsimberidou AM, Hong DS, Ye Y, Cartwright C, Wheler JJ, Falchook GS, Naing A, Fu S, Piha-Paul S, Janku F, Meric-Bernstam F, Hwu P, Kee B, Kies MS, Broaddus R, Mendelsohn J, Hess KR, Kurzrock R.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00002. Epub 2017 Sep 8.

35.

Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours.

Schöffski P, Gordon M, Smith DC, Kurzrock R, Daud A, Vogelzang NJ, Lee Y, Scheffold C, Shapiro GI.

Eur J Cancer. 2017 Nov;86:296-304. doi: 10.1016/j.ejca.2017.09.011. Epub 2017 Oct 20.

36.

Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach.

Kato S, Kurasaki K, Ikeda S, Kurzrock R.

Oncologist. 2018 Feb;23(2):171-178. doi: 10.1634/theoncologist.2017-0199. Epub 2017 Oct 16.

37.

Genomics of Immunotherapy-Associated Hyperprogressors-Response.

Kato S, Kurzrock R.

Clin Cancer Res. 2017 Oct 15;23(20):6376. doi: 10.1158/1078-0432.CCR-17-1990. No abstract available.

38.

Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities.

Costa R, Costa RB, Talamantes SM, Helenoswki I, Carneiro BA, Chae YK, Gradishar WJ, Kurzrock R, Giles FJ.

Oncotarget. 2017 Jun 29;8(40):67782-67789. doi: 10.18632/oncotarget.18847. eCollection 2017 Sep 15.

39.

Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy.

Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, Bazhenova LA, Kurzrock R.

Clin Cancer Res. 2017 Oct 1;23(19):5729-5736. doi: 10.1158/1078-0432.CCR-17-1439.

40.

Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability.

Bieg-Bourne CC, Millis SZ, Piccioni DE, Fanta PT, Goldberg ME, Chmielecki J, Parker BA, Kurzrock R.

Cancer Res. 2017 Nov 15;77(22):6313-6320. doi: 10.1158/0008-5472.CAN-17-1569. Epub 2017 Sep 22.

PMID:
28939679
41.

Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns.

Nikanjam M, Patel H, Kurzrock R.

Oncoimmunology. 2017 Jun 28;6(8):e1338997. doi: 10.1080/2162402X.2017.1338997. eCollection 2017.

42.

The biology of Hepatocellular carcinoma: implications for genomic and immune therapies.

Khemlina G, Ikeda S, Kurzrock R.

Mol Cancer. 2017 Aug 30;16(1):149. doi: 10.1186/s12943-017-0712-x. Review.

43.

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.

Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R.

Mol Cancer Ther. 2017 Nov;16(11):2598-2608. doi: 10.1158/1535-7163.MCT-17-0386. Epub 2017 Aug 23.

PMID:
28835386
44.

BRAF mutation as a novel driver of eosinophilic cystitis.

Choi MY, Tsigelny IF, Boichard A, Skjevik ÅA, Shabaik A, Kurzrock R.

Cancer Biol Ther. 2017 Sep 2;18(9):655-659. doi: 10.1080/15384047.2017.1360449. Epub 2017 Aug 22.

45.

Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing.

Schwaederle M, Chattopadhyay R, Kato S, Fanta PT, Banks KC, Choi IS, Piccioni DE, Ikeda S, Talasaz A, Lanman RB, Bazhenova L, Kurzrock R.

Cancer Res. 2017 Oct 1;77(19):5419-5427. doi: 10.1158/0008-5472.CAN-17-0885. Epub 2017 Aug 14.

46.
47.

A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma.

Vergote IB, Smith DC, Berger R, Kurzrock R, Vogelzang NJ, Sella A, Wheler J, Lee Y, Foster PG, Weitzman R, Buckanovich RJ.

Eur J Cancer. 2017 Sep;83:229-236. doi: 10.1016/j.ejca.2017.06.018. Epub 2017 Jul 26.

48.

Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act.

Kehl KL, Fullmer CP, Fu S, George GC, Hess KR, Janku F, Karp DD, Kato S, Kizer CK, Kurzrock R, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, Hong DS.

Clin Cancer Res. 2017 Jul 20. doi: 10.1158/1078-0432.CCR-16-3027. [Epub ahead of print]

PMID:
28729355
49.

Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients.

Heestand GM, Schwaederle M, Gatalica Z, Arguello D, Kurzrock R.

Eur J Cancer. 2017 Sep;83:80-87. doi: 10.1016/j.ejca.2017.06.019. Epub 2017 Jul 17.

50.

Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit.

Kato S, Subbiah V, Kurzrock R.

J Natl Compr Canc Netw. 2017 Jul;15(7):863-866. doi: 10.6004/jnccn.2017.0127. No abstract available.

PMID:
28687573

Supplemental Content

Loading ...
Support Center